| Source of record | UK Trials |
| ISRCTN | ISRCTN35362654 |
| Date ISRCTN assigned | 19/08/2002 |
| Local reference number(s) | MRC UKALL XA |
| Public title | Medical Research Council Adult Acute Lymphoblastic Leukaemia Trial UKALL XA |
| Scientific title |
|
| Acronym | N/A |
| Disease/condition/study domain | Leukaemia (acute) |
| Study hypothesis | Not provided at time of registration. |
| Design/methodology | Randomised controlled trial |
| Research ethics review | Not provided at time of registration. |
| Countries of trial | United Kingdom |
| Participants - inclusion criteria | 1. Newly diagnosed ALL
2. Aged >25 years |
| Participants - exclusion criteria | Not provided at time of registration. |
| Patient information material |
|
| Anticipated start date | 01/01/1985 |
| Anticipated end date | 31/12/1992 |
| Status of trial | Completed |
| Target number of participants | Number of participants entered into the trial, added as of 29/06/2007: 618 |
| Interventions | All patients receive induction, central nervous system (CNS) prophylaxis and maintenance.
Patients are randomised to one of four treatment arms:
1. Arm A: Early intensification therapy to be given immediately after induction and before CNS prophylaxis.
2. Arm B: Late intensification therapy to be given following cranial radiotherapy at week 20 of maintenance.
3. Arm C: Intensification therapy to be given both immediately after induction and following cranial radiotherapy at week 20 of maintenance.
4. Arm D: No intensification therapy.
INDUCTION: Chemotherapy with vincristine, prednisolone, asparaginase, daunorubicin and intrathecal methotrexate.
INTENSIFICATION: Intensification therapy with vincristine, prendisolone, daunorubicin, thioguanine, etoposide, cytosine arabinoside and intrathecal methotrexate.
CNS PROPHYLAXIS: Cranial radiotherapy, intrathecal methotrexate plus mercaptopurine.
MAINTENANCE: Maintenance therapy consisting of daily mercaptopurine, weekly methotrexate, monthly vincristine plus prednisolone. Treatment to be given for total of two years following complete remission. |
| Primary outcome measure(s) | Not provided at time of registration. |
| Secondary outcome measure(s) | Not provided at time of registration. |
| Publications | Results: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9359507 |
| Sources of funding | Medical Research Council (UK) |
| Sponsor name | Medical Research Council (UK) |
| Sponsor details | 20 Park Crescent
London
United Kingdom
W1B 1AL |
| Sponsor telephone | +44 (0)20 7636 5422 |
| Sponsor fax | +44 (0)20 7436 6179 |
| Sponsor email | clinical.trial@headoffice.mrc.ac.uk |
| Sponsor website | http://www.mrc.ac.uk |
| Contact name | Dr - - |
| Contact details | UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA |
| Contact telephone | +44 (0) 20 7670 4723 |
| Contact fax | +44 (0) 20 7670 4818 |
| Contact email | register@ctu.mrc.ac.uk |
| More information | For more up-to-date information please go to the ISRCTN link below. |
| Link to record in ISRCTN Register | ISRCTN35362654 |
| Date last extracted from ISRCTN register | 17/04/2008 |
